How Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates

Simply Wall St.06:21

In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619176805?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218","is_english":true,"pubTime":"2026-03-15 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619176805","market":"nz","top_or_hot":-1,"title":"How Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates","media":"Simply Wall St.","content":"<div>\n<p>In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-dividend-obesity-dru\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-dividend-obesity-dru><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-dividend-obesity-dru\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2112291526.USD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-dividend-obesity-dru","article_id":"2619176805","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-dividend-obesity-dru","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619176805","pubTimestamp":1773526889,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, featuring senior leaders in rare disease and finance.\nTogether with analyst commentary emphasizing MariTide in obesity and the Repatha VESALIUS-CV trial, these updates underscored how Amgen’s expanding portfolio and pipeline execution are shaping investor views amid ongoing biosimilar pressures.\nWe...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","CSII":"Cardiovascular Systems","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4211":"区域性银行","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4534":"瑞士信贷持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4566":"资本集团","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","ISBC":"投资者银行","AMGN":"安进","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4082":"医疗保健设备","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"投资者如何应对安进(AMGN)股息、肥胖药物焦点和心血管试验更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"CSII":1.5,"AMGN":1.5},"content_text":"In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, featuring senior leaders in rare disease and finance. Together with analyst commentary emphasizing MariTide in obesity and the Repatha VESALIUS-CV trial, these updates underscored how Amgen’s expanding portfolio and pipeline execution are shaping investor views amid ongoing biosimilar pressures. We will now examine how Amgen’s strong 2025 growth and highlighted obesity and cardiovascular pipeline programs affect its existing investment narrative. Find 48 companies with promising cash flow potential yet trading below their fair value.AdvertisementAmgen Investment Narrative RecapTo own Amgen, you generally need to believe its obesity, cardiovascular, and rare disease pipelines can offset biosimilar and pricing pressures while supporting steady earnings and cash generation. The new dividend and Leerink conference appearance do not alter the main near term catalyst, which remains clinical and commercial progress for MariTide and Repatha, nor the key risk of biosimilar erosion in aging franchises, though they do reinforce confidence in execution and capital returns. The most relevant update here is the US$2.52 per share second quarter 2026 dividend. For many shareholders, a consistent, growing dividend is central to the Amgen thesis, especially as the company increases R&D and capital spending. That payout, funded alongside double digit 2025 revenue and EPS growth, matters when weighing pipeline catalysts such as MariTide and VESALIUS CV against concerns about margin pressure from rising costs and biosimilar competition. Yet beneath Amgen’s strong pipeline story, investors should still be aware of how accelerating biosimilar competition could... Read the full narrative on Amgen (it's free!)Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028.Uncover how Amgen's forecasts yield a $327.74 fair value, a 11% downside to its current price.Exploring Other PerspectivesAMGN 1-Year Stock Price Chart While consensus focuses on pipeline upside, the most pessimistic analysts were modeling revenue drifting to about US$34.4 billion and earnings to roughly US$5.2 billion, reminding you that views on Amgen’s long term pressure from aging drugs and new rivals can differ sharply and that this latest news could eventually shift both optimistic and bearish narratives.Explore 4 other fair value estimates on Amgen - why the stock might be worth 11% less than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.Ready To Venture Into Other Investment Styles?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Uncover the next big thing with 29 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619176805","isCrawlerRequest":true}